High-risk myeloma: a gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

被引：51

作者：

Zhan, Fenghuang ^{[1
]}

Barlogie, Bart ^{[1
]}

Mulligan, George ^{[1
]}

Shaughnessy, John D., Jr. ^{[1
]}

Bryant, Barb ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

来源：

BLOOD | 2008年 / 111卷 / 02期

关键词：

D O I：

10.1182/blood-2007-10-119321

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：968 / 969

页数：2

共 7 条

[1]

CHNG WJ, 2007, LEUKEMIA 1129

[2] Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia [J].

Ferrando, AA ;

Neuberg, DS ;

Staunton, J ;

Loh, ML ;

Huard, C ;

Raimondi, SC ;

Behm, FG ;

Pui, CH ;

Downing, JR ;

Gilliland, DG ;

Lander, ES ;

Golub, TR ;

Look, AT .

CANCER CELL, 2002, 1 (01) :75-87

[3] Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib [J].

Mulligan, George ;

Mitsiades, Constantine ;

Bryant, Barb ;

Zhan, Fenghuang ;

Chng, Wee J. ;

Roels, Steven ;

Koenig, Erik ;

Fergus, Andrew ;

Huang, Yongsheng ;

Richardson, Paul ;

Trepicchio, William L. ;

Broyl, Annemiek ;

Sonneveld, Pieter ;

Shaughnessy, John D., Jr. ;

Bergsagel, P. Leif ;

Schenkein, David ;

Esseltine, Dixie-Lee ;

Boral, Anthony ;

Anderson, Kenneth C. .

BLOOD, 2007, 109 (08) :3177-3188

[4] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [J].

Richardson, PG ;

Sonneveld, P ;

Schuster, MW ;

Irwin, D ;

Stadtmauer, EA ;

Facon, T ;

Harousseau, JL ;

Ben-Yehuda, D ;

Lonial, S ;

Goldschmidt, H ;

Reece, D ;

San-Miguel, JF ;

Bladé, J ;

Boccadoro, M ;

Cavenagh, J ;

Dalton, WS ;

Boral, AL ;

Esseltine, DL ;

Porter, JB ;

Schenkein, D ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) :2487-2498

[5] Gene expression profiling of pediatric acute myelogenous leukemia [J].

Ross, ME ;

Mahfouz, R ;

Onciu, M ;

Liu, HC ;

Zhou, XD ;

Song, GC ;

Shurtleff, SA ;

Pounds, S ;

Cheng, C ;

Ma, J ;

Ribeiro, RC ;

Rubnitz, JE ;

Girtman, K ;

Williams, WK ;

Raimondi, SC ;

Liang, DC ;

Shih, LY ;

Pui, CH ;

Downing, JR .

BLOOD, 2004, 104 (12) :3679-3687

[6] Signatures of the immune response [J].

Shaffer, AL ;

Rosenwald, A ;

Hurt, EM ;

Giltnane, JM ;

Lam, LT ;

Pickeral, OK ;

Staudt, LM .

IMMUNITY, 2001, 15 (03) :375-385

[7] A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 [J].

Shaughnessy, John D. ;

Zhan, Fenghuang ;

Burington, Bart E. ;

Huang, Yongsheng ;

Colla, Simona ;

Hanamura, Ichiro ;

Stewart, James P. ;

Kordsmeier, Bob ;

Randolph, Christopher ;

Williams, David R. ;

Xiao, Yan ;

Xu, Hongwei ;

Epstein, Joshua ;

Anaissie, Elias ;

Krishna, Somashekar G. ;

Cottler-Fox, Michele ;

Hollmig, Klaus ;

Mohiuddin, Abid ;

Pineda-Roman, Mauricio ;

Tricot, Guido ;

van Rhee, Frits ;

Sawyer, Jeffrey ;

Alsayed, Yazan ;

Walker, Ronald ;

Zangari, Maurizio ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2007, 109 (06) :2276-2284

← 1 →